WO2001045560A1 - Procede pour determiner des indices relatifs au sang et dispositif correspondant - Google Patents
Procede pour determiner des indices relatifs au sang et dispositif correspondant Download PDFInfo
- Publication number
- WO2001045560A1 WO2001045560A1 PCT/RU1999/000507 RU9900507W WO0145560A1 WO 2001045560 A1 WO2001045560 A1 WO 2001045560A1 RU 9900507 W RU9900507 W RU 9900507W WO 0145560 A1 WO0145560 A1 WO 0145560A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- channels
- κanalοv
- unit
- blοκ
- activity
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 40
- 210000004369 blood Anatomy 0.000 title abstract description 5
- 239000008280 blood Substances 0.000 title abstract description 5
- 230000000694 effects Effects 0.000 claims abstract description 52
- 230000005855 radiation Effects 0.000 claims abstract description 16
- 238000004458 analytical method Methods 0.000 claims description 20
- 230000033764 rhythmic process Effects 0.000 claims description 11
- 238000004891 communication Methods 0.000 claims description 8
- 238000012545 processing Methods 0.000 claims description 8
- 230000008569 process Effects 0.000 claims description 7
- 238000011160 research Methods 0.000 claims description 6
- 238000001228 spectrum Methods 0.000 claims description 2
- 241001538234 Nala Species 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 230000007717 exclusion Effects 0.000 claims 1
- 230000003595 spectral effect Effects 0.000 claims 1
- 238000012731 temporal analysis Methods 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 43
- 239000008103 glucose Substances 0.000 abstract description 43
- 201000010099 disease Diseases 0.000 abstract description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 17
- 238000003745 diagnosis Methods 0.000 abstract description 11
- 238000001467 acupuncture Methods 0.000 abstract description 5
- 230000010365 information processing Effects 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 2
- 108091006146 Channels Proteins 0.000 description 94
- 238000012360 testing method Methods 0.000 description 29
- 238000004364 calculation method Methods 0.000 description 14
- 210000004185 liver Anatomy 0.000 description 14
- 206010012601 diabetes mellitus Diseases 0.000 description 12
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 12
- 238000011156 evaluation Methods 0.000 description 11
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 210000002784 stomach Anatomy 0.000 description 8
- 210000004907 gland Anatomy 0.000 description 7
- 102000004877 Insulin Human genes 0.000 description 6
- 108090001061 Insulin Proteins 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 229940125396 insulin Drugs 0.000 description 6
- 239000000090 biomarker Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 210000000265 leukocyte Anatomy 0.000 description 4
- 239000011575 calcium Substances 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 2
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 2
- 238000012742 biochemical analysis Methods 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000010183 spectrum analysis Methods 0.000 description 2
- 229940116269 uric acid Drugs 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010073306 Exposure to radiation Diseases 0.000 description 1
- 241000208202 Linaceae Species 0.000 description 1
- 235000004431 Linum usitatissimum Nutrition 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 101100400378 Mus musculus Marveld2 gene Proteins 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 201000008191 cerebritis Diseases 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 235000013410 fast food Nutrition 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 206010024378 leukocytosis Diseases 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000008533 pain sensitivity Effects 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000001020 rhythmical effect Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000013179 statistical model Methods 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 230000029305 taxis Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 238000004804 winding Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/68—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient
- A61B5/6801—Arrangements of detecting, measuring or recording means, e.g. sensors, in relation to patient specially adapted to be attached to or worn on the body surface
- A61B5/6802—Sensor mounted on worn items
- A61B5/681—Wristwatch-type devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/14546—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue for measuring analytes not otherwise provided for, e.g. ions, cytochromes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue
- A61B5/1455—Measuring characteristics of blood in vivo, e.g. gas concentration, pH value; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid, cerebral tissue using optical sensors, e.g. spectral photometrical oximeters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4854—Diagnosis based on concepts of traditional oriental medicine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
- A61B5/316—Modalities, i.e. specific diagnostic methods
- A61B5/318—Heart-related electrical modalities, e.g. electrocardiography [ECG]
- A61B5/346—Analysis of electrocardiograms
- A61B5/349—Detecting specific parameters of the electrocardiograph cycle
Definitions
- the shared indicator may not be disregarded.
- the present invention is a non-invasive process.
- Another offer of the invention is a description of the non-invasive designation of the various indicators in person. 2
- the device contains a radiation source operating in the near-infrared region of the detector and located above the shared body part. They emit radiation through a separate part of the body and, through it, are received, the received signals are received and received by us
- liver diseases are associated with certain changes in the biochemistry of the liver, for example, the content of bilirubin, white blood cells, and
- the concentra- tion of indicators of the partition is divided in the form of a divided fraction
- the channels are related to the function of the basic physical systems, as well as to the system and related to them,
- a non-invasive method of separating the indicators of the use of devices is used for the use of non-invasive devices.
- Task ⁇ edlagaem ⁇ g ⁇ iz ⁇ b ⁇ e ⁇ eniya yavlyae ⁇ sya ⁇ az ⁇ ab ⁇ a noninvariant zivn ⁇ g ⁇ s ⁇ s ⁇ ba ⁇ edeleniya u ⁇ vnya glyu ⁇ zy, d ⁇ ugi ⁇ bi ⁇ imiches ⁇ i ⁇ and ⁇ menny ⁇ ⁇ aza ⁇ eley ⁇ vi on ⁇ sn ⁇ vanii ⁇ tsen ⁇ i a ⁇ ivn ⁇ s ⁇ i ⁇ e- delonny ⁇ a ⁇ u ⁇ un ⁇ u ⁇ ny ⁇ ⁇ anal ⁇ v in ⁇ m including ⁇ ealn ⁇ m v ⁇ emeni in ⁇ ezhime ⁇ s ⁇ yann ⁇ g ⁇ m ⁇ ni ⁇ inga.
- the energy activity of the channels can be divided up and
- 25 ENG channel can be used in time intervals between ⁇ -
- Glucose ⁇ vi 24 - 6.1 ⁇ + 6.4 ⁇ - 14 ⁇ - 4.0 ⁇ + 5.2 ⁇
- stomach channels ( ⁇ ), the intestines are important.
- Evaluation of the energy activity of the channels that are active can only be attributed to the fact that people are involved in the exploitation of human activity.
- a number of surveys of one patient are conducted in the dynamics of his observation with the use of an individual model of dependencies.
- ⁇ ⁇ ivedonny ⁇ in ⁇ isanii ⁇ ablitsa ⁇ for ene ⁇ ge ⁇ iches ⁇ i ⁇ ⁇ anal ⁇ v is ⁇ lz ⁇ vany ⁇ scheu ⁇ ebi ⁇ elnye ⁇ b ⁇ znacheniya: ⁇ - ⁇ anal log ⁇ i ⁇ , 01- ⁇ anal ⁇ ls ⁇ g ⁇ ⁇ ishechni ⁇ a, uS- ⁇ anal ⁇ e ⁇ i ⁇ a ⁇ da, ⁇ - ⁇ anal ⁇ yn ⁇ g ⁇ ⁇ b ⁇ g ⁇ eva ⁇ elya, C- ⁇ anal se ⁇ dtsa, 10- ⁇ ana ⁇ ⁇ n ⁇ g ⁇ ⁇ ishechni ⁇ a, ⁇ - ⁇ anal
- the concentration of some indicators of the circle and, in particular, glucose are mainly estimated at the base of the 5 assets available.
- 15 activities of the separate channels can be divided by results of the studies of differences in the age of the patient and the diagnosis of the group.
- the evaluation of the channel’s activity level may occur with the help of the distribution of the activity of the channel associated with the activity of the channel.
- Isomer and the rate of its concentration in the area is connected with the liver cells with a larger external component.
- the basic function of the baking channel has an accessible level of glucose in the country, the general level of function.
- the left side of the channel of the liver is associated with cells that have a left-hand side of the compressed air, which is associated with a reduction in the outcome of the disease.
- the analogous regulatory channel mechanism has places and regulates the other components of the circuit. 14
- the proposed method of quantitatively evaluating the indicators of profitability is carried out by the following method:
- the 20th phase of research determines the indicators of the highest energy activity of the interesting channels of the channel. (For more details, see Application No. 98106432/14, publ. “Inventions”, ° 1, 2000)
- 25 taxes may be paid to the test of Gabana, Folla, Kazakstani, etc.
- ch ⁇ v ⁇ zdey- s ⁇ vuya ⁇ s ⁇ yannym ⁇ m ⁇ schn ⁇ s ⁇ i is ⁇ chni ⁇ m ⁇ e ⁇ la, schi ⁇ aya ⁇ i e ⁇ m v ⁇ e- on me in se ⁇ unda ⁇ on ⁇ edelonnye B ⁇ ⁇ anal ⁇ v or ⁇ dn ⁇ sya ⁇ it used ⁇ chni ⁇ ⁇ e ⁇ la ⁇ e ⁇ i ⁇ diches ⁇ i, na ⁇ ime ⁇ in ⁇ a ⁇ with ⁇ uls ⁇ m, ⁇ edelyayu ⁇ ⁇ - 5 liches ⁇ v ⁇ v ⁇ zdeys ⁇ vy / ⁇ ass ⁇ v / d ⁇ manifestations of painful sensations.
- ⁇ n na ⁇ di ⁇ sya in gi ⁇ un ⁇ tsii ⁇ chisl ⁇ ⁇ e ⁇ l ⁇ vy ⁇ v ⁇ zdeys ⁇ vy d ⁇ ⁇ yavleniya b ⁇ levy ⁇ ⁇ schuscheny ⁇ ez ⁇ v ⁇ z ⁇ as ⁇ ae ⁇ ⁇ s ⁇ avneniyu with ⁇ bychnym s ⁇ s ⁇ yaniem and na ⁇ b ⁇ if ⁇ anal na ⁇ di ⁇ sya on vys ⁇ m ene ⁇ ge ⁇ iches ⁇ m u ⁇ vne in th gi ⁇ e ⁇ un ⁇ tsii, ⁇ chisl ⁇ ⁇ a ⁇ i ⁇ v ⁇ zdeys ⁇ vy d ⁇ ⁇ yavleniya b ⁇ levy ⁇ ⁇ schuscheny ⁇ ez ⁇ ⁇ adae ⁇ ,
- test ⁇ pulses may also be used in the low-frequency generator GZ-111. Negative impulses synchronized with a pulsed wave were given to the ZL-107B LED.
- two types of devices may be used. ⁇ One of them, a portable portable device, is being tested. In the event of a test involving the end-users and the IR-radiation, the results of the evaluation of the activity of the separate channels with the public are separate from the public
- the proposed equipment may be available for you.
- Us ⁇ ys ⁇ v ⁇ s ⁇ de ⁇ zhi ⁇ bl ⁇ ⁇ egis ⁇ atsii se ⁇ dechn ⁇ g ⁇ ⁇ i ⁇ ma (1) bl ⁇ u ⁇ avleniya (2) bl ⁇ da ⁇ chi ⁇ a v ⁇ emeni (3), and bl ⁇ ⁇ egis ⁇ atsii ⁇ b- ⁇ ab ⁇ i in ⁇ matsii (4) bl ⁇ ⁇ b ⁇ azheniya in ⁇ matsii (5) bl ⁇ bi- s ⁇ nneg ⁇ m ⁇ dema connection bl ⁇ bi- s ⁇ nneg ⁇ m ⁇ dema connection
- Evaluation of the activity of the accelerator channels is carried out by the interference of the pulses of the IR-radiation
- the control unit is equipped with a keypad for entering commands and information.
- the unit of registration and processing of information was performed on a basic microprocessor (for example, on the basis of an independent process) ⁇
- the IS-DIID type is Zi ⁇ P-107B.
- the communication unit with the computer is based on the basic information of the two-sided interface, which allows the user to transmit information to the user.
- the supplying pulses are transmitted to the B synchronously with the pulsed wave (using the pulse sensor) or the C-wave, through the synchronization via the EG-channel. With this, we count the number of test impulses for every other case of the outbreak of illness. If the channel is in a low power function, then the number of test pulses will be larger and more general level of the channel function.
- the optional “self-learning of the system” is also possible due to the testing of all channels with simultaneous biomedical diseases.
- the initial model is so long as it takes into account changes in the course of the disease and the other factors.
- the sum of the values of the indicators of 24 channels is found for each of the channels in the channel model (in this case, it is equal to 168), and the average value is 7 (7). Then, each of the indicators for the channels is divided into the average value. The resulting result is entered in the formula. For women with diabetes mellitus 1 type of analogous adult group of the history of glucose dependence in the presence of an increase in the incidence of the disease.
- the direct measurement of the glucose level for analyzing the glucose from the finger was 5.7 m / l.
- Example 4 Patient G., 66 years. IB ⁇ 1785-s. It suffers from diabetes mellitus 2 and 2.
- Table 8 The results of the channel test are presented in Table 8.
- the level of glucose was 17.0 mols / l.
- the level of the nation was 141 mol / l.
- This method of valuation prevents the use of daily monitoring and other biological indicators of real time.
- Leukocytes 2.93 + 0.63 ⁇ + 0.04 ⁇ - 0.26 ⁇ - 0.13 ⁇ + 0.02 ⁇
- Eritocytes 4.1 + 0.02 ⁇ + 0.34 ⁇ - 0.14 ⁇ - 0.07 ⁇ + 0.02 ⁇
- the proposed method went to medical treatment, in particular in one of the hospitals in the city of Saint-Petersburg, Russia. Question for the period 1998-1999 It was used to divide indicators of more than 250 patients.
- the proposed method is available and allows reliable and reliable results to be obtained.
- Devices for the implementation of a non-invasive method of separating indicators of convenience are convenient for use and can be used in daily operation.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/RU1999/000507 WO2001045560A1 (fr) | 1999-12-21 | 1999-12-21 | Procede pour determiner des indices relatifs au sang et dispositif correspondant |
AU30866/00A AU3086600A (en) | 1999-12-21 | 1999-12-21 | Method for determining blood indexes and a device for embodying thereof |
DE19983992T DE19983992B4 (de) | 1999-12-21 | 1999-12-21 | Verfahren zur Bestimmung von Blutcharakteristiken |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/RU1999/000507 WO2001045560A1 (fr) | 1999-12-21 | 1999-12-21 | Procede pour determiner des indices relatifs au sang et dispositif correspondant |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001045560A1 true WO2001045560A1 (fr) | 2001-06-28 |
Family
ID=20130426
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/RU1999/000507 WO2001045560A1 (fr) | 1999-12-21 | 1999-12-21 | Procede pour determiner des indices relatifs au sang et dispositif correspondant |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU3086600A (ar) |
DE (1) | DE19983992B4 (ar) |
WO (1) | WO2001045560A1 (ar) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0160768A1 (en) * | 1984-05-04 | 1985-11-13 | Kurabo Industries Ltd. | Spectrophotometric apparatus for the non-invasive determination of glucose in body tissues |
RU2110248C1 (ru) * | 1992-12-30 | 1998-05-10 | Валерий Геннадьевич Мужиков | Способ коррекции аритмий сердца, не связанных с органическими нарушениями, и устройство для рефлексотерапии |
RU2122208C1 (ru) * | 1989-10-28 | 1998-11-20 | Сак Янг Вон | Способ и устройство для измерения концентрации глюкозы в крови |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5383909A (en) * | 1993-01-29 | 1995-01-24 | Medtronic, Inc. | Diagnostic telemetry system for an apparatus for detection and treatment of tachycardia and fibrillation |
WO1996013201A1 (en) * | 1993-05-07 | 1996-05-09 | Diasense, Inc. | Non-invasive measurement of analyte concentration in blood |
DE4342105A1 (de) * | 1993-12-12 | 1995-06-14 | Cho Ok Kyung | Verfahren und Vorrichtung zur noninvasiven Bestimmung der Konzentration der Glucose in Teilen des menschlichen Körpers, inbesondere im menschlichen Blut, unter Durchführung höchstgenauer Temperaturmessungen des menschlichen Körpers |
US5553613A (en) * | 1994-08-17 | 1996-09-10 | Pfizer Inc. | Non invasive blood analyte sensor |
AT610U1 (de) * | 1995-01-23 | 1996-02-26 | Knaipp Ortwin Mag | Langzeit-pulsmess-armbanduhr mit speicher |
DE19841217B4 (de) * | 1997-10-27 | 2005-06-16 | Applied Photonics Worldwide, Inc., Reno | Gerät und Verfahren zur spektroskopischen Analyse von menschlichem oder tierischem Gewebe oder Körperfluiden |
-
1999
- 1999-12-21 WO PCT/RU1999/000507 patent/WO2001045560A1/ru active Application Filing
- 1999-12-21 AU AU30866/00A patent/AU3086600A/en not_active Abandoned
- 1999-12-21 DE DE19983992T patent/DE19983992B4/de not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0160768A1 (en) * | 1984-05-04 | 1985-11-13 | Kurabo Industries Ltd. | Spectrophotometric apparatus for the non-invasive determination of glucose in body tissues |
RU2122208C1 (ru) * | 1989-10-28 | 1998-11-20 | Сак Янг Вон | Способ и устройство для измерения концентрации глюкозы в крови |
RU2110248C1 (ru) * | 1992-12-30 | 1998-05-10 | Валерий Геннадьевич Мужиков | Способ коррекции аритмий сердца, не связанных с органическими нарушениями, и устройство для рефлексотерапии |
Also Published As
Publication number | Publication date |
---|---|
DE19983992B4 (de) | 2009-07-23 |
AU3086600A (en) | 2001-07-03 |
DE19983992T1 (de) | 2002-12-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wardell et al. | Biological correlates of Reiki Touchsm healing | |
Joshi et al. | iGLU 2.0: A new wearable for accurate non-invasive continuous serum glucose measurement in IoMT framework | |
Vitale | An integrative review of Reiki touch therapy research | |
Umair et al. | HRV and stress: A mixed-methods approach for comparison of wearable heart rate sensors for biofeedback | |
Mossberg | Reliability of a timed walk test in persons with acquired brain injury | |
Segman | Device and method for noninvasive glucose assessment | |
EP0612500A1 (en) | Method and device for diagnosis of living organism | |
CN101359220B (zh) | 基于脑功能计测的外部环境控制装置 | |
WO2002087434A1 (fr) | Procede d'evaluation de l'efficacite d'un etat biologique et d'une action modifiant un etat biologique, appareil et systeme d'evaluation, programme d'evaluation et support d'enregistrement dudit programme | |
JP2009515576A (ja) | 高血圧等の心臓血管系疾患の管理又は制御のためのシステム及び方法 | |
Halberg et al. | Engineering and governmental challenge: 7-day/24-hour chronobiologic blood pressure and heart rate screening: Part I | |
EP1221034B1 (en) | Method and system for imaging the dynamics of scattering medium | |
Bowman et al. | Counselor trainee anxiety during the initial counseling interview. | |
WO2020221265A1 (zh) | 无创人体血液组分浓度的监测方法及设备 | |
Amira et al. | Monitoring chronic disease at home using connected devices | |
GB2410084A (en) | Brain activity infra-red measurement device | |
US6527730B2 (en) | Reducing noise in a technique for diagnosing attention deficit hyperactivity disorder | |
EP1219233A2 (en) | Using image modification and temperature biofeedback to diagnose and treat Attention Deficit Hyperactivity Disorder (ADHD) | |
US7937139B2 (en) | Systems and methods of utilizing electrical readings in the determination of treatment | |
Drachev et al. | Study profile: Oral health assessment among participants of “Epidemiology of cardiovascular diseases in Russian regions. Third study” in the Arkhangelsk region | |
Bundzen et al. | Psychophysiological correlates of athletic success in athletes training for the Olympics | |
Parker et al. | Accuracy and precision of opportunistic measures of body composition from the Tanita DC-430U | |
WO2001045560A1 (fr) | Procede pour determiner des indices relatifs au sang et dispositif correspondant | |
Hammerschlag et al. | Inter-rater agreement of biofield tuning: testing a novel health assessment procedure | |
Tarnanas et al. | Functional impairment in virtual-reality-daily-living-activities as a defining feature of amnestic mci: Cognitive and psychomotor correlates |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA CH CN CZ DE FI HU IL JP KR NO NZ PL RU SK UA US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
RET | De translation (de og part 6b) |
Ref document number: 19983992 Country of ref document: DE Date of ref document: 20021205 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 19983992 Country of ref document: DE |
|
122 | Ep: pct application non-entry in european phase | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8607 |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8607 |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8607 |